Vuong Duthinh
Cardiovascular Disease · Grand Blanc, MINPI 1760459911
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,100 and has fallen 93.7% since, to $69 in 2023.
Across 209 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$499
- Johnson & Johnson$295
- Astellas Pharma US Inc$282
- Boehringer Ingelheim$265
- Amgen$262
- Abbott$228
- plus $2K from 23 others
Across 9 payments — averaging $504.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$3K
- Boehringer Ingelheim$2K
What the payments were for
- Food & beverage$3,18295%
- Education$1775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 36 | $499 |
| Johnson & Johnson(2 entities) | 24 | $295 |
| Astellas Pharma US Inc | 8 | $282 |
| Boehringer Ingelheim | 16 | $265 |
| Amgen | 15 | $262 |
| Abbott | 15 | $228 |
| Bayer | 14 | $221 |
| AstraZeneca | 11 | $147 |
| Actelion Pharmaceuticals US, Inc. | 7 | $137 |
| Pfizer | 7 | $94 |
| E.r. Squibb & Sons, L.L.C. | 7 | $91 |
| Lundbeck LLC | 5 | $83 |
| Merck | 5 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $80 |
| Edwards Lifesciences | 4 | $77 |
| Inari Medical, Inc. | 1 | $69 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $67 |
| Bardy Diagnostics, Inc. | 4 | $55 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Vifor Pharma, Inc. | 2 | $47 |
| Philips North America LLC | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $24 |
| Medtronic | 1 | $19 |
| Sanofi | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $13 |
| United Therapeutics Corporation | 1 | $13 |
How this compares
$3,359 in reported general payments places this provider in the 55th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Grand Blanc
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.